Open Mobile Menu
OUR PIPELINE

Innovative
therapies for
novel disease
targets

ZielBio is developing a pipeline of novel therapeutics for multiple diseases with high unmet need, starting with cancer.
A dense, pink-purple cell with long, dark blue, branching projections
Programs
Target
Class
Indication
Discovery
Pre-Clinical
Phase 1
Phase 2
Cancer-Specific Plectin (CSP)
ZB131
Program (Class)
ZB131 (mAb)
Cancer-Specific Plectin (CSP)
mAb
Indication
Advanced Solid Tumors (PDAC, Ovarian, Bile Duct)
Phase 1
ZB131 is a first-in-class clinical-stage monoclonal antibody with a high affinity to and specificity for cancer-specific plectin (CSP). CSP is a novel target identified by ZielBio’s proprietary platform found to be exclusively mislocalized to the surface of cancer cells.
Combination Therapy ZB131 + Gemcitibine
Program (Class)
Combination Therapy ZB131 + Gemcitibine (mAb)
Cancer-Specific Plectin (CSP)
mAb
Indication
Advanced Solid Tumors
Pre-Clinical
ZB131 +/- combinations
Program (Class)
ZB131 +/- combinations (mAb)
Cancer-Specific Plectin (CSP)
mAb
Indication
CSP Biomarker Driven (Tumor Agnostic)
Pre-Clinical
Undisclosed
ZB520
Program (Class)
ZB520 (mAb)
Undisclosed
mAb
Indication
Advanced Solid Tumors (Renal Cancers)
Pre-Clinical
Undisclosed
Undisclosed
Program (Class)
Undisclosed (mAb Radio pharmaceutical)
Undisclosed
mAb Radio pharmaceutical
Indication
Advanced Solid Tumors
Discovery
Undisclosed
Program (Class)
Undisclosed (ADC)
Undisclosed
ADC
Indication
Undisclosed
Discovery

ZielBio uses proprietary technology to identify novel disease targets and design better, safer therapeutics for people with cancer and other serious diseases.